Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.70 EUR
Change Today -0.041 / -1.50%
Volume 0.0
EZB On Other Exchanges
Symbol
Exchange
New York
As of 2:15 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

enzo biochem inc (EZB) Snapshot

Open
€2.60
Previous Close
€2.74
Day High
€2.70
Day Low
€2.56
52 Week High
09/9/14 - €4.66
52 Week Low
02/24/15 - €2.19
Market Cap
122.3M
Average Volume 10 Days
40.0
EPS TTM
--
Shares Outstanding
45.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENZO BIOCHEM INC (EZB)

enzo biochem inc (EZB) Related Businessweek News

No Related Businessweek News Found

enzo biochem inc (EZB) Details

Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 35 patient service centers in New York and New Jersey; and a standalone laboratory in the New York, as well as a full-service phlebotomy, in-house logistics department, and information technology department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

433 Employees
Last Reported Date: 10/9/14
Founded in 1976

enzo biochem inc (EZB) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $555.5K
Co-Founder, President, Chief Financial Office...
Total Annual Compensation: $492.7K
Senior Vice President of Finance
Total Annual Compensation: $123.8K
Vice President of Corporate Development
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2014.

enzo biochem inc (EZB) Key Developments

Enzo Biochem, Inc. Announces New York State Department of Health Grants Conditional Approval for Enzo Clinical Labs

Enzo Biochem Inc. announced that the New York State Department of Health has granted conditional approval for Enzo Clinical Labs' use of the FlowScript assay in detection of mRNA from HPV oncogenes, E6 and E7. Overexpression of these HPV oncogenes promotes the growth of malignant cells to the development of cervical cancer. As a result, Enzo Clinical Labs may now begin to offer the assay to its clientele. In addition, relevant reagents will be marketed though Enzo's Life Sciences division. The FlowScript technology platform is a proprietary, flow cytometry-based, molecular detection system for the multiplex analysis of cell function and identity, and was developed by cross-functional teams at Enzo Biochem. The HPV E6/E7 assay is the first product to utilize this novel platform. Analysis is performed on a small volume of a liquid cytology specimen and can thus be easily incorporated as a reflex test measure following abnormal Pap smear results. The assay, and the platform on which it is based, allows for the simultaneous analysis of several different genes expressed in every cell in a given sample. In this manner, it is possible to produce clinically relevant data at the single cell level. Unlike other assays that study mRNA expression, FlowScript assays are performed by a homogenous system that eliminates washing steps that can reduce fluctuation of results. Additionally, the assay's use of external control improves run-to-run consistency. As a result, both hands on time and the number of steps are reduced, allowing for improved economics. In data presented at a recent pathology conference in Italy, Enzo's assay was shown to produce reliable and consistent results near the limit of assay detection. Furthermore, Enzo anticipates applying this platform to a multiplicity of uses such as the study of other cancers, the evaluation of an individual immune state as well as products targeted to the drug development market, among others.

Enzo Biochem Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended January 31, 2015

Enzo Biochem Inc. reported unaudited earnings results for the second quarter and six months ended January 31, 2015. For the quarter, revenues were $23.1 million, up from $22.9 million a year ago. The operating loss totaled $3.9 million, compared to $3.6 million a year ago. Net loss was $4.1 million or $0.09 per basic and diluted share compared to $3.57 million or $0.09 per basic and diluted share a year ago. Loss before income taxes was $4.205 million against $3.570 million a year ago. LBITDA was $3.221 million against $2.516 million a year ago. Adjusted LBITDA was $3.221 million against $2.516 million a year ago. Non GAAP net loss was $4.090 million or $0.09 per basic and diluted share against $3.566 million or $0.09 per basic and diluted share a year ago. For the six months, revenues were $47.916 million against $47.061 million a year ago. Operating loss approximated $7.0 million, up from $6.6 million a year ago. Net loss was $7.8 million or $0.17 per basic and diluted share against $6.35 million, or $0.15 per basic and diluted share a year ago. Loss before income taxes was $7.812 million against $6.295 million a year ago. LBITDA was $5.821 million against $4.154 million a year ago. Adjusted LBITDA was $5.821 million against $4.154 million a year ago. Non GAAP net loss was $7.820 million or $0.17 per basic and diluted share million against $6.353 million or $0.15 per basic and diluted share a year ago.

Enzo Biochem Inc. to Report Q2, 2015 Results on Mar 12, 2015

Enzo Biochem Inc. announced that they will report Q2, 2015 results on Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EZB:GR €2.70 EUR -0.041

EZB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NanoString Technologies Inc $10.55 USD -0.08
NeoGenomics Inc $4.77 USD +0.05
Psychemedics Corp $16.55 USD +0.25
Response Genetics Inc $0.45 USD -0.0035
WaferGen Bio-systems Inc $4.47 USD +0.117
View Industry Companies
 

Industry Analysis

EZB

Industry Average

Valuation EZB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZO BIOCHEM INC, please visit www.enzo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.